Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay

Journal of Pharmaceutical Sciences

Volumn 99, Issue 7, 2010, Pages 3246-3265

  Skolnik, Suzanne ^a   Lin, Xuena ^a   Wang, Jianling ^a   Chen, Xiao Hui ^a   He, Timothy ^a,b   Zhang, Bailin ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ADME; Bioavailability; Caco 2 cells; Efflux pumps; In vitro in vivo correlations (IVIVC); Intestinal absorption; P glycoprotein; Paracellular transport; Permeability; Recovery

Indexed keywords

AMFEBUTAMONE; AMILORIDE; AMPHOTERICIN B; AZTREONAM; BOVINE SERUM ALBUMIN; BROMAZEPAM; DEXAMETHASONE; ENALAPRILAT; ETHIONAMIDE; FELODIPINE; FENOTEROL; GANCICLOVIR; GUANABENZ; KETOCONAZOLE; LISINOPRIL; LOPERAMIDE; MIBEFRADIL; MITOXANTRONE; OMEPRAZOLE; OXACILLIN; OXAZEPAM; PINDOLOL; PRAVASTATIN; PROPYLTHIOURACIL; QUINIDINE; RESERPINE; SULFADIAZINE; TENIDAP; TERBINAFINE; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; ARTIFICIAL MEMBRANE; CELL ASSAY; CELL STRAIN CACO 2; CELL TRANSPORT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG MARKETING; DRUG PENETRATION; DRUG SOLUBILITY; EFFUSION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; NONHUMAN; NONLINEAR SYSTEM; PHYSICAL CHEMISTRY; PREDICTIVE VALIDITY; RAT; VALIDATION PROCESS;

EID: 77953303004     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22080     Document Type: Article

References (102)

1. Carlson TJ, Fisher MB. 2008. Recent advances in high throughput screening for ADME properties. Comb Chem High Throughput Screen 11:258-264.
2. Wang J, Urban L, Bojanic D. 2007. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin Drug Metab Toxicol 3:641-665. (Pubitemid 351320635)
3. Van de Waterbeemd H. 2005. From in vivo to in vitro/in silico ADME: Progress and challenges. Expert Opin Drug Metab Toxicol 1:1-4.
4. Wang J. 2009. Comprehensive assessment of ADMET risks in drug discovery. Curr Pharm Des 15:2195-2219.
5. Zhu C, Jiang L, Chen TM, Hwang KK. 2002. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 37:399-407. (Pubitemid 34465549)
6. Sugano K, Takata N, Machida M, Saitoh K, Terada K. 2002. Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model. Int J Pharm 241:241-251. (Pubitemid 34718026)
7. Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885.
8. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88:28-33. (Pubitemid 29037364)
9. Matsson P, Bergstrom CA, Nagahara N, Tavelin S, Norinder U, Artursson P. 2005. Exploring the role of different drug transport routes in permeability screening. J Med Chem 48:604-613. (Pubitemid 40139802)
10. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, Kindmark A, Artursson P. 2006. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29:269-277. (Pubitemid 44602404)
11. Balimane PV, Patel K, Marino A, Chong S. 2004. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur J Pharm Biopharm 58:99-105. (Pubitemid 38781010)
12. Marino AM, Yarde M, Patel H, Chong S, Balimane PV. 2005. Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. Int J Pharm 297:235-241. (Pubitemid 40720282)
13. Galkin A, Pakkanen J, Vuorela P. 2008. Development of an automated 7-day 96-well Caco-2 cell culture model. Pharmazie 63:464-469. (Pubitemid 351955409)
14. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628. (Pubitemid 32979675)
15. Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. 2008. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.
16. Mandagere AK, Thompson TN, Hwang KK. 2002. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304-311.
17. Cai H, Stoner C, Reddy A, Freiwald S, Smith D, Winters R, Stankovic C, Surendran N. 2006. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. Int J Pharm 308:133-139. (Pubitemid 43097244)
18. Nestorov I. 2007. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235-249. (Pubitemid 47321518)
19. Parrott N, Jones H, Paquereau N, Lave T. 2005. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin Pharmacol Toxicol 96:193-199. (Pubitemid 40387995)
20. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511-542.
21. Wohnsland F, Faller B. 2001. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 44:923-930. (Pubitemid 32861617)
22. Fagerholm U. 2007. Prediction of human pharmacokinetics - Gastrointestinal absorption. J Pharm Pharmacol 59:905-916. (Pubitemid 47051070)
23. Cheng KC, Li C, Uss AS. 2008. Prediction of oral drug absorption in humans - From cultured cell lines and experimental animals. Expert Opin Drug Metab Toxicol 4:581-590. (Pubitemid 351890740)
24. Fagerholm U. 2008. The role of permeability in drug ADME/PK, interactions and toxicity - Presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans. Pharm Res 25:625-638. (Pubitemid 351357725)
25. Tavelin S, Taipalensuu J, Soderberg L, Morrison R, Chong S, Artursson P. 2003. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm Res 20:397-405. (Pubitemid 36288368)
26. Shirasaka Y, Sakane T, Yamashita S. 2008. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 97:553-565.
27. Pade V, Stavchansky S. 1997. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res 14:1210-1215. (Pubitemid 27432545)
28. Adson A, Raub TJ, Burton PS, Barsuhn CL, Hilgers AR, Audus KL, Ho NF. 1994. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. J Pharm Sci 83:1529-1536. (Pubitemid 24348320)
29. Adson A, Burton PS, Raub TJ, Barsuhn CL, Audus KL, Ho NF. 1995. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: Uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J Pharm Sci 84:1197-1204.
30. Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos 36:1650-1658.
31. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H. 2000. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195-204. (Pubitemid 30190095)
32. Neuhoff S, Ungell AL, Zamora I, Artursson P. 2003. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: Implications for drug-drug interactions. Pharm Res 20:1141-1148. (Pubitemid 36951837)
33. Fossati L, Dechaume R, Hardillier E, Chevillon D, Prevost C, Bolze S, Maubon N. 2008. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs. Int J Pharm 360:148-155.
34. Palmgren JJ, Monkkonen J, Korjamo T, Hassinen A, Auriola S. 2006. Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm 64:369-378. (Pubitemid 44585210)
35. Krishna G, Chen K, Lin C, Nomeir AA. 2001. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm 222:77-89. (Pubitemid 32525789)
36. Crespi CL, Penman BW, Hu M. 1996. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4. Pharm Res 13:1635-1641. (Pubitemid 26426885)
37. Zhou L, Yang L, Tilton S, Wang J. 2007. Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery. J Pharm Sci 96: 3052-3071. (Pubitemid 350221202)
38. Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K. 2000. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm Res 17:1175-1180.
39. Kataoka M, Masaoka Y, Yamazaki Y, Sakane T, Sezaki H, Yamashita S. 2003. In vitro system to evaluate oral absorption of poorly water-soluble drugs: Simultaneous analysis on dissolution and permeation of drugs. Pharm Res 20:1674-1680.
40. Saha P, Kou JH. 2002. Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eur J Pharm Biopharm 54:319-324. (Pubitemid 35341832)
41. Neuhoff S, Artursson P, Zamora I, Ungell AL. 2006. Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells. Pharm Res 23:350-359. (Pubitemid 43239592)
42. Lakeram M, Lockley DJ, Pendlington R, Forbes B. 2008. Optimisation of the Caco-2 permeability assay using experimental design methodology. Pharm Res 25:1544-1551.
43. Rege BD, Kao JP, Polli JE. 2002. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16:237-246.
44. Collnot EM, Baldes C, Wempe MF, Kappl R, Huttermann J, Hyatt JA, Edgar KJ, Schaefer UF, Lehr CM. 2007. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: Influence on ATPase activity and membrane fluidity. Mol Pharm 4:465-474. (Pubitemid 46983960)
45. Seelig A, Gerebtzoff G. 2006. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opin Drug Metab Toxicol 2:733-752. (Pubitemid 46118318)
46. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, Coffin M. 1999. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 16:1812-1817. (Pubitemid 30040695)
47. Johnson BM, Charman WN, Porter CJ. 2002. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 4:E40.
48. Varma MV, Perumal OP, Panchagnula R. 2006. Functional role of P-glycoprotein in limiting peroral drug absorption: Optimizing drug delivery. Curr Opin Chem Biol 10:367-373. (Pubitemid 44080650)
49. Igel S, Drescher S, Murdter T, Hofmann U, Heinkele G, Tegude H, Glaeser H, Brenner SS, Somogyi AA, Omari T, Schafer C, Eichelbaum M, Fromm MF. 2007. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin Pharmacokinet 46:777-785. (Pubitemid 47347449)
50. Usansky HH, Hu P, Sinko PJ. 2008. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. Drug Metab Dispos 36:863-869. (Pubitemid 351574883)
51. Beaumont K, Harper A, Smith DA, Bennett J. 2000. The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671. Eur J Pharm Sci 12:41-50.
52. Kunta JR, Sinko PJ. 2004. Intestinal drug transporters: In vivo function and clinical importance. Curr Drug Metab 5:109-124.
53. Lin JH. 2003. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81.
54. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. 1999. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci 88:1067-1072.
55. Hochman JH, Yamazaki M, Ohe T, Lin JH. 2002. Evaluation of drug interactions with P-glycoprotein in drug discovery: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr Drug Metab 3:257-273.
56. Gleeson MP. 2008. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51:817-834.
57. Artursson P, Ungell AL, Lofroth JE. 1993. Selective paracellular permeability in two models of intestinal absorption: Cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 10:1123-1129.
58. Tavelin S, Taipalensuu J, Hallbook F, Vellonen KS, Moore V, Artursson P. 2003. An improved cell culture model based on 2/ 4/A1 cell monolayers for studies of intestinal drug transport: Characterization of transport routes. Pharm Res 20:373-381.
59. Nagahara N, Tavelin S, Artursson P. 2004. Contribution of the paracellular route to the pH-dependent epithelial permeability to cationic drugs. J Pharm Sci 93:2972-2984.
60. Saitoh R, Sugano K, Takata N, Tachibana T, Higashida A, Nabuchi Y, Aso Y. 2004. Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm Res 21:749-755.
61. Fine KD, Santa Ana CA, Porter JL, Fordtran JS. 1995. Effect of changing intestinal flow rate on a measurement of intestinal permeability. Gastroenterology 108:983-989.
62. Tanaka Y, Taki Y, Sakane T, Nadai T, Sezaki H, Yamashita S. 1995. Characterization of drug transport through tight-junctional pathway in Caco-2 monolayer: Comparison with isolated rat jejunum and colon. Pharm Res 12:523-528.
63. Chiou WL, Barve A. 1998. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792-1795.
64. Lau YY, Krishna G, Yumibe NP, Grotz DE, Sapidou E, Norton L, Chu I, Chen C, Soares AD, Lin CC. 2002. The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios. Pharm Res 19:1606-1610.
65. Pollack GM, Brouwer KL, Demby KB, Jones JA. 1990. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose. Drug Metab Dispos 18:197-202.
66. www.tp-search.jp [accessed January to March 2007].
67. Norinder U, Haeberlein M. 2003. Calculated molecular properties and multivariate statistical analysis in absorption prediction. In: van de Waterbeemd H, Lennernas H, Artursson P, editors. Drug bioavailability, methods and principles in medicinal chemistry series. Weinheim: Wiley-VCH Verlag GmbH & Co. pp 358-405.
68. Menez C, Buyse M, Besnard M, Farinotti R, Loiseau PM, Barratt G. 2006. Interaction between miltefosine and amphotericin B: Consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Antimicrob Agents Chemother 50:3793-3800.
69. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Butina D, Beck G, Sherborne B, Cooper I, Platts JA. 2001. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure - activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 90:749-784.
70. Mahony WB, Domin BA, Zimmerman TP. 1991. Ganciclovir permeation of the human erythrocyte membrane. Biochem Pharmacol 41:263-271.
71. Raevsky OA, Schaper KJ, Artursson P, McFarland JW. 2002. A novel approach for prediction of intestinal absorption of drugs in humans based on hydrogen bond descriptors and structural similarity. Quant Stract-Act Relat 20:402-413.
72. Swaan PW, Stehouwer MC, Tukker JJ. 1995. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: Enalapril, enalaprilat, and lisinopril. Biochim Biophys Acta 1236: 31-38.
73. Yamashita S, Hattori E, Shimada A, Endoh Y, Yamazaki Y, Kataoka M, Sakane T, Sezaki H. 2002. New methods to evaluate intestinal drug absorption mediated by oligopeptide transporter from in vitro study using Caco-2 cells. Drug Metab Pharmacokinet 17:408-415.
74. Luckner P, Brandsch M. 2005. Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: Analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm 59:17-24.
75. Varma MV, Sateesh K, Panchagnula R. 2005. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: Contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm 2:12-21.
76. Stenberg P, Norinder U, Luthman K, Artursson P. 2001. Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 44:1927-1937.
77. Da VG, Zerrouk N, Richard I, Frendo JL, Zhiri A, Li-Khuan R, Tricottet V, Provot G, Chaumeil JC, Arnaud P. 2004. Short term Caco-2/TC7 cell culture: Comparison between conventional 21-d and a commercially available 3-d system. Biol Pharm Bull 27:1986-1992.
78. Bolger MB, Agoram B, Fraczkiewicz R, Steere B. 2003. Simulation of absorption, metabolism, and bioavailability. In: van de Waterbeemd H, Lennernas H, Artursson P, editors. Drug bioavailability, methods and principles in medicinal chemistry series, 18th edition. Weinheim: Wiley-VCH Verlag GmbH & Co. pp 420-443.
79. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. 2001. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364:551-557.
80. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T. 2003. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2:105-112.
81. Benet LZ, Cummins CL, Wu CY. 2004. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9.
82. Wang YH, Li Y, Yang SL, Yang L. 2005. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model 45: 750-757.
83. Bertelsen KM, Greenblatt DJ, von Moltke LL. 2006. Apparent active transport of MDMA is not mediated by P-glycoprotein: A comparison with MDCK and Caco-2 monolayers. Biopharm Drug Dispos 27:219-227.
84. Skold C, Winiwarter S, Wernevik J, Bergstrom F, Engstrom L, Allen R, Box K, Comer J, Mole J, Hallberg A, Lennernas H, Lundstedt T, Ungell AL, Karlen A. 2006. Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. J Med Chem 49:6660-6671.
85. Gochoco CH, Ryan FM, Miller J, Smith PL, Hidalgo IJ. 1994. Uptake and transepithelial transport of the orally absorbed cephalosporin cephalexin, in the human intestinal cell line, Caco-2. Int J Pharm 104:187-202.
86. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P. 2000. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 89:63-75.
87. Bode H, Brendel E, Ahr G, Fuhr U, Harder S, Staib AH. 1996. Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur J Clin Pharmacol 50:195-201.
88. Crivori P, Reinach B, Pezzetta D, Poggesi I. 2006. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharm 3:33-44.
89. Neuhaus W, Bogner E, Wirth M, Trzeciak J, Lachmann B, Gabor F, Noe CR. 2006. A novel tool to characterize paracellular transport: TheAPTS-dextran ladder. PharmRes 23:1491-1501.
90. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
91. Liang E, Proudfoot J, Yazdanian M. 2000. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm Res 17:1168-1174.
92. Volk EL, Schneider E. 2003. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543.
93. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. 2006. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247-1254. (Pubitemid 43920885)
94. Flanagan SD, Benet LZ. 1999. Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum. Pharm Res 16:221-224.
95. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. 2006. Breast cancer resistance protein (BCRP/ ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
96. Troutman MD, Thakker DR. 2003. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20:1200-1209.
97. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B. 2001. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285:111-117. (Pubitemid 32912517)
98. Gan LS, Yanni S, Thakker DR. 1998. Modulation of the tight junctions of the Caco-2 cell monolayers by H2-antagonists. Pharm Res 15:53-57. (Pubitemid 28080866)
99. Yee S. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - Fact or myth. Pharm Res 14:763-766.
100. Collett A, Sims E, Walker D, He YL, Ayrton J, Rowland M, Warhurst G. 1996. Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption. Pharm Res 13:216-221. (Pubitemid 26072141)
101. Dahan A, Sabit H, Amidon GL. 2009. Multiple efflux. Pumps are involved in the transepithelial transport of colchicine: Combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 10:2028-2036.
102. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)